With the rise of TKIs, the treatment landscape of #SystemicMastocytosis is changing, and the future looks promising. Join us on February 10 to learn as experts discuss the latest advances in TKI therapy, safety and side effects, and more. Register at https://ow.ly/mAUb50Y1kS3#SystemicMastocytosis#MedSky #mastocytosis

New research provides a #genomic framework with the ability to distinguish biologically malignant from indolent #myeloma precursor states in #MGUS and SMM, with key genomic alterations identified as predictors of faster progression in transformed cases: https://ow.ly/MWAm50Y1jFK#genomic#myeloma#MGUS#HemeSky #MMsm

Care on Hold: Prior authorization may directly affect patients with #cancer, according to an analysis which found that 74% of patients had to seek prior authorization for their treatment, and 50% were directly involved in the authorization process. #MedSky #OncSky

The January issue is out now! Issue highlights include meeting coverage and reports from #ASH25, a feature on #patient support programs, updates on international guidelines for #pediatric #AcuteMyeloidLeukemia #AML, and more. See the full lineup here: https://ow.ly/tgpq50Y0C89

RD118, a new anti-GPRC5D #CARTtherapy, may be an effective therapeutic option in heavily pretreated cases of #MultipleMyeloma #MMsm, including those relapsing after BCMA therapy, according to phase I research resulting in a durable ORR of 94.4%: https://ow.ly/FQGQ50XXspe#CARTtherapy#MultipleMyeloma#MMsm#HemeSky #MyelomaSky

Among older and frail patients with #MultipleMyeloma #MMsm, a dexamethasone-sparing regimen with #daratumumab and #lenalidomide reduced the risk of progression or death compared with lenalidomide and #dexamethasone alone, at a PFS of 53.4 vs. 22.5 months: https://ow.ly/YXzG50XT7Aw#MultipleMyeloma#MMsm#daratumumab#lenalidomide#dexamethasone#HemeSky #OncSky

According to recent research, peripheral #blood testing may offer a reliable, minimally invasive alternative to bone marrow evaluation for somatic mutation surveillance in #pediatric patients with #BoneMarrowFailure and #leukemia predisposition syndromes: https://ow.ly/TTeZ50XUak8#blood#pediatric#BoneMarrowFailure#leukemia#HemeSky #MedSky

See what's to come in this month's issue! Editor-in-Chief Bethany Samuelson Bannow, MD, MCR (she/her) shares what readers can expect, including coverage from #ASH25, a feature on #patient assistance programs, a challenging case of refractory #Hodgkin #lymphoma, and more: https://ow.ly/Bnww50XT7Uw

New data point to an association between medical imaging #radiation and an increased risk of #hematologic #cancer in children and adolescents, with researchers estimating 10.1% of hematologic cancers may have been attributable to such radiation exposure: https://ow.ly/KEzp50XSwSs#radiation#hematologic#cancer#HemeSky #OncSky

Recent research indicates that #isatuximab monotherapy could be another safe and effective treatment option for patients with R/R #amyloidosis, with the therapy resulting in an ORR of 77%, including 57% with a VGPR or better: https://ow.ly/wbFU50XNrsR#isatuximab#amyloidosis#HemeSky

Chemo-free combination therapy with ATRA-ATO produced a significantly higher two-year EFS than SOC ATRA plus #chemotherapy among patients with newly diagnosed, high-risk acute promyelocytic #leukemia at 88% vs. 71%: https://ow.ly/kjxH50XNnbU#chemotherapy#leukemia#HemeSky #OncSky

KP104, a #monoclonal #antibody used to treat #PNH, continues to display strong clinical efficacy two years after treatment, with 100% of participants maintaining an Hb increase of at least 2 g/dL from baseline and 89% achieving Hb normalization by then: https://ow.ly/veiT50XNmTt#monoclonal#antibody#PNH#HemeSky

Compared with #obinutuzumab monotherapy, the next-gen BTK inhibitor #zanubrutinib in combination with #obinutuzumab led to improved survival in patients with #FollicularLymphoma, resulting in ORRs of 70.3% vs. 44.4% and PFS of 22.1 vs. 10.3 months: https://ow.ly/qzV250XMMvj#obinutuzumab#zanubrutinib#obinutuzumab#FollicularLymphoma#HemeSky #MedSky

Antibody-based combination therapy with #teclistamab and #daratumumab was shown to be highly effective in elderly patients with newly diagnosed #MultipleMyeloma #MMsm, producing a VGPR or better in 79% of patients and MRD negativity in 100% at six months: https://ow.ly/KQKn50XMHAW#teclistamab#daratumumab#MultipleMyeloma#MMsm#HemeSky #MedSky

A 600 mg daily dose of the menin inhibitor #ziftomenib, combined with venetoclax and azacitidine, demonstrated robust clinical activity in patients with newly diagnosed, NPM1-mutated #AcuteMyeloidLeukemia #AML at an 84% CRc and an MRD-negative rate of 54%: https://ow.ly/E5Nb50XMwL0#ziftomenib#AcuteMyeloidLeukemia#AML#HemeSky #OncSky

For patients with #PolycythemiaVera, #rusfertide provided durable, sustained hematocrit control that stayed below 43% and reduced #phlebotomy requirements up to 52 weeks, with 61.9% of patients remaining ineligible for phlebotomy between 0-52 weeks: https://ow.ly/KYiZ50XKVRT#PolycythemiaVera#rusfertide#phlebotomy#HemeSky #MedSky

For patients with myeloid/lymphoid #neoplasms with FGFR1 rearrangements, #pemigatinib led to high rates of complete clinical and cytogenetic responses in chronic-phase disease, at 96% and 88%, respectively, with encouraging activity in blast-phase disease: https://ow.ly/UKCT50XKhvX#neoplasms#pemigatinib#HemeSky #OncSky

According to a recent analysis of the iStopMM study, individuals with smoldering multiple myeloma #MMsm (SMM) had a 36% higher risk of infections compared with individuals with MGUS or those without either SMM or MGUS: https://ow.ly/RWcE50XH9Nz#MMsm#HemeSky #myeloma

#ASH25 In patients with #myelofibrosis, the mutant CALR-specific monoclonal antibody INCA33989 was well tolerated as monotherapy or in combination with #ruxolitinib, with 37% and 30% of patients having SVR25 and SVR35, respectively, at 24 weeks: https://ow.ly/4FX950XF6zZ#ASH25#myelofibrosis#ruxolitinib#HemeSky #MedSky

#ASH25 The BCL2 inhibitor #sonrotoclax produced good responses in patients with treatment-naïve CLL/SLL when combined with #obinutuzumab, with ORRs of 89% across all patients and 93% at a 320 mg dose: https://ow.ly/M8uB50XF6zT#ASH25#sonrotoclax#obinutuzumab#HemeSky #MedSky

#ASH25 In the first head-to-head study of the two drugs, #pirtobrutinib was found to produce ORRs that were noninferior to those seen with #ibrutinib in both the intent-to-treat and R/R population of patients with #CLL: https://ow.ly/WIEg50XExWA#ASH25#pirtobrutinib#ibrutinib#CLL#HemeSky #OncSky

#ASH25 Among patients with #ChronicLymphocyticLeukemia, fixed-duration targeted treatment using venetoclax-based combinations was found to achieve efficacy comparable to #BTKi therapy, with 3-year PFS ranging from 79% to 81% across all treatment arms: https://ow.ly/LOkJ50XExRg#ASH25#ChronicLymphocyticLeukemia#BTKi#HemeSky #OncSky

#ASH25 Based on findings from the largest prospective analysis of #renal impairment in patients with #PolycythemiaVera (PV), a history of #thromboembolism, high-risk PV, and elevated LDH were found to be associated with rapid decline in #kidney function: https://ow.ly/AmqA50XExMH#ASH25#renal#PolycythemiaVera#thromboembolism#kidney#HemeSky #MedSky

A frailty-score-adapted treatment regimen of an oral PI/IMiD combination improved early treatment cessation, PFS, and OS in unfit patients with #MultipleMyeloma #MMsm but not in frail patients, according to research to presented at #ASH25: https://ow.ly/rtun50XCYcp#MultipleMyeloma#MMsm#ASH25#HemeSky #MyelomaSky

#ASH25 Anito-cel, a new anti-BMCA #CARTcell therapy with a unique D-domain binder that may lead to more therapeutic efficacy, was found to produce strong rates of response in patients with R/R #MultipleMyeloma #MMsm, with an ORR of 97% and CR/sCR of 68%: https://ow.ly/P9Gj50XCNnl#ASH25#CARTcell#MultipleMyeloma#MMsm#HemeSky #OncSky

Results from the phase II Shorespan-004 trial, to be presented at #ASH25, indicate that oral #bomedemstat effectively reduced hematocrit to less than 45% by week 36 in 45% of patients with previously treated #PolycythemiaVera: https://ow.ly/2bmS50XCMyM#ASH25#bomedemstat#PolycythemiaVera#HemeSky #MedSky

Imaging's Hidden Cost: There may be a link between #medical #imaging and childhood #BloodCancers. A retrospective cohort study found that 10.1% of #hematologic cancers in children may be caused by #radiation exposure from medical imaging. #HemeSky #OncSky

The December issue is available now! Check out the link below to read articles on #isatuximab for R/R AL #amyloidosis, ATRA-ATO combination therapy for APL, #pemigatinib for myeloid & lymphoid #neoplasms with FGFR1 rearrangements, and more: https://ow.ly/fzzm50XARLQ

A longer time from T-cell collection to infusion of #CARTcell therapy was associated with worse outcomes, particularly with regard to PFS and OS, in patients with R/R #DLBCL, according to findings from a small retrospective trial conducted in Japan: https://ow.ly/SwTh50XAlhw

Health Care Musical Chairs: #Burnout and dissatisfaction among #healthcare workforce may lead to lower retention rates. Results from the Harris Poll found that 55% of health care workers plan to switch jobs in 2026. #HemeSky #MedSky

See what's to come in the December issue of ASH Clinical News! Highlights of next month's issue include articles on the past, present, and future of #hematology, rethinking the classification of #myeloid #neoplasms, early treatment in #MCL, and more: https://ow.ly/ngmg50XxL5o#hematology#myeloid#neoplasms#MCL#HemeSky

According to recent findings, erythroid-predominant #MyelodysplasticSyndromes #MDS, found to be characterized by frequent multi-hit #TP53 alterations and BCL-XL upregulation, is also associated with poor outcomes after #venetoclax-based therapy: https://ow.ly/HAMr50XwV6o#MyelodysplasticSyndromes#MDS#TP53#venetoclax-based#HemeSky

Combination treatment with #talquet­amab plus #daratumumab demonstrated deep, durable responses in patients with heavily pretreated R/R #MMsm #myeloma, with 71% and 82% achieving a response, and safety consistent with each as monotherapy: https://ow.ly/cSkt50Xv8vP#talquet­amab#daratumumab#MMsm#myeloma#HemeSky #MyelomaSky #OncSky

In a small study of #pediatric patients with high-risk #AML, the combination of FLAG-IDA plus #venetoclax appeared to be a highly effective frontline treatment regimen, with all patients achieving CR and most proceeding to #hematopoietic cell #transplant: https://ow.ly/a1Cm50Xu4Xv#pediatric#AML#venetoclax#hematopoietic#transplant#HemeSky #leukemia

Airborne Ailments: Air #pollution from oil and gas affects the health and well-being of thousands of Americans each year. A study found that air pollution contributes to 1,610 #cancer cases annually. #OncSky #MedSky

FT516, an engineered, off-the-shelf NK cell product derived from induced pluripotent stem cells, demonstrated meaningful clinical activity in patients with R/R B-cell #lymphomas in a phase I trial, with an ORR of 58%, along with a favorable safety profile: https://ow.ly/7AMq50XqMof#lymphomas#HemeSky #OncSky

A new, more sensitive #assay used to find KIT p.D816V, a critical mutation in #MCAS and #mastocytosis, could improve disease detection and diagnosis by identifying cases of disease that are more difficult to find through other means or are undetectable: https://ow.ly/bxWV50XpHwm#assay#MCAS#mastocytosis#HemeSky #MedSky

Scrubs and Scarcity: Food insecurity remains a serious issue across the country, including among #medical #students. Research found that 21.2% of medical students experience food insecurity, compared to 13.5% of U.S. households. #HemeSky #MedSky

Among patients with #MultipleMye­loma #MMsm treated with conventional #chemotherapy, #proteasome inhibitors, and/or #immunomodulatory agents, long-​term PFS was found to be associated with achieving complete response and being diagnosed at a younger age: https://ow.ly/eMNC50Xon5h#MultipleMye­loma#MMsm#chemotherapy#proteasome#immunomodulatory#HemeSky #OncSky

The November issue is out now! Highlights include a cover story on medical #misinformation and articles on FLAG-IDA plus #venetoclax in #pediatric #AML, off-the-shelf NK cell therapy in R/R B-cell #lymphoma, and more. Check out the full lineup here: https://ow.ly/KJcM50XmEte#misinformation#venetoclax#pediatric#AML#lymphoma#HemeSky #MedSky

In patients with #ChronicLymphocyticLeukemia #CLL, the use of regular prophylactic IgG replacement therapy to help prevent #infection, a common occurrence with the disease, was not associated with a reduced risk of infection-related hospitalizations: https://ow.ly/6L3W50XlOHU#ChronicLymphocyticLeukemia#CLL#infection#HemeSky #MedSky

Cancer Deaths and #Obesity: Obesity-related #cancer deaths continue to rise. An analysis of the #CDC WONDER database found that age-adjusted #mortality rates increased from 3.73 to 13.52 per million between 1999 and 2020. #OncSky #MedSky

See what's to come in the next issue! Highlights of the November issue include a feature on medical #misinformation among patients, an in-depth look at #CastlemanDisease, the latest from ASH's Blood Journals' Portfolio, and more: https://ow.ly/wZLs50XiZLR#misinformation#CastlemanDisease#HemeSky #MedSky

p53 #immunohistochemistry could be a useful and more timely surrogate testing method for early characterization of #TP53 mutations, as testing correctly identified the mutation in 95.5% of tested patients with #MDS and 100% of patients with #AML: ow.ly/NShb50Xik5U #HemeSky #leukemia #OncSky

Despite the widespread clinical practice of inducing CR before #alloHCT in patients with R/R #AML, findings from the ASAP trial challenge this standard, with evidence showing that genetics, not remission status, determine overall survival after #transplant: ow.ly/eiu450Xgxxi #HemeSky #leukemia

For patients with #MultipleMyeloma #MMsm receiving BCMA-targeted #CARTcell therapy, #ExtramedullaryDisease was found to be associated with severe toxicities, particularly ICANS and ICAHT, prolonged #neutropenia, and increased non-relapse mortality: ow.ly/aV8I50Xgxbe #HemeSky #Myeloma #OncSky

Implant Implications: In addition to #anaplastic large-cell #lymphomas (ALCL), breast implants following #mastectomy may be linked to other lymphomas. A study of 61,000+ women found five cases of #DLBCL, two of SLL, and one of peripheral #Tcell lymphoma, plus seven cases of ALCL. #HemeSky #OncSky

New research supports the assertion that a post-induction intermediate dose of #cytarabine may be sufficient to prevent relapse with less toxicity compared with a high dose in newly diagnosed #AML, as both doses resulted in similar rates of five-year OS: ow.ly/rlaZ50XcIef #HemeSky #OncSky #leukemia

In patients newly diagnosed with #MultipleMyeloma #MMsm and #transplant eligible, treatment with an induction regimen of #IsaKRD resulted in the highest rates of pretransplant MRD negativity reported to date at 66% at 10⁻⁵ and 50% at 10⁻⁶: ow.ly/8euE50Xbhiy #HemeSky #OncSky #myeloma

A recent cohort study on #clonal #hematopoiesis of indeterminate potential (CHIP) has demonstrated that it may modestly increase the risk of #VenousThromboembolism (VTE), as 4.5% of CHIP carriers experienced a #VTE, compared with 3.2% of noncarriers: ow.ly/5mZR50Xb0EX #HemeSky #thrombosis